Phase III Trial to Investigate Efficacy & Safety of Vilobelimab in

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06092216` - Spesolimab in Pyoderma Gangrenosum	Phase 2
Completed	`NCT03311464` - A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan	Phase 3
Recruiting	`NCT04901325` - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Phase 2
Completed	`NCT00791557` - Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease	N/A
Terminated	`NCT02318914` - A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum	Phase 3
Terminated	`NCT02315417` - An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum	Phase 3
Completed	`NCT03137160` - An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum	Phase 2
Not yet recruiting	`NCT05984654` - Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum	N/A
Completed	`NCT04895566` - Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma	Early Phase 1
Withdrawn	`NCT04274166` - Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Phase 2
Completed	`NCT01882504` - Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum	Phase 2
Withdrawn	`NCT00730717` - Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum	Phase 2
Completed	`NCT03971643` - Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum	Phase 2
Not yet recruiting	`NCT04792957` - JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
Not yet recruiting	`NCT05821374` - Deucravacitinib in PG	Early Phase 1
Terminated	`NCT03072953` - Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum	Phase 2
Recruiting	`NCT05120726` - A Novel Therapeutic Treatment of Pyoderma Gangrenosum	Phase 4
Withdrawn	`NCT00690846` - Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	Phase 2
Completed	`NCT01965613` - A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum	Phase 2
Recruiting	`NCT01952275` - Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases	N/A

NCT number	NCT05964413
Study type	Interventional
Source	InflaRx GmbH
Contact	Dorothee Neukirchen, Dr.
Phone	+49 89 4141897800
Email	clinicaltrials@inflarx.de
Status	Recruiting
Phase	Phase 3
Start date	August 15, 2023
Completion date	May 15, 2026

Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms